Research Interests: Treatment, Risk assessment, Cardiovascular Risk, Stroke, Humans, and 24 moreHypertension, Cox Regression, Female, Male, Atrial Fibrillation, Follow-up studies, Incidence, Risk factors, Multiple Linear Regression, Clinical Sciences, Aged, Middle Aged, Risk Factor, Left ventricular hypertrophy, Clinical Assessment, Cardiovascular Diseases, Risk Factors, Risk Assessment, Losartan, Predictive value of tests, Time varying, Mitral regurgitation, Atenolol, and Left Atrium
Research Interests:
The blood pressure (BP) response during a maximal ergometer bicycle test was studied in 190 apparently healthy subjects (95 men and 95 women) aged 21-70 years. The starting load was 50 W and was increased by 50 W every 4 min until... more
The blood pressure (BP) response during a maximal ergometer bicycle test was studied in 190 apparently healthy subjects (95 men and 95 women) aged 21-70 years. The starting load was 50 W and was increased by 50 W every 4 min until exhaustion. Mean physical performance expressed as cumulative work was 2276 +/- 789 W in men and 1109 +/- 276 W in women (P less than 0.0001). The maximum heart rate was similar in men and women and declined significantly with age (r = -0.78, P less than 0.001 for men and r = -0.64, P less than 0.0001 for women). The mean maximal systolic blood pressure (MSBP) was 193 +/- 23 mmHg in men and 171 +/- 21 mmHg in women (P less than 0.0001). Men aged greater than or equal to 50 years had a MSBP of 201 +/- 22 mmHg, compared to 188 +/- 22 mmHg in those aged less than 50 years (P less than 0.01). Women aged greater than or equal to 60 years had a MSBP of 190 +/- 21 mmHg compared to 166 +/- 19 mmHg in their younger counterparts (P less than 0.001). The diastolic BP showed a similar modest increase at all ages and in both sexes. SBP is dependent on age and gender and this must be taken into consideration when assessing a normal response in individual patients.
Research Interests:
To assess the long-term course of regression of left ventricular hypertrophy (LVH) and haemodynamic changes during spirapril treatment, 11 male hypertensive patients with a left ventricular mass (LVM) > 240 g and a mean age of 48... more
To assess the long-term course of regression of left ventricular hypertrophy (LVH) and haemodynamic changes during spirapril treatment, 11 male hypertensive patients with a left ventricular mass (LVM) > 240 g and a mean age of 48 (range 41-60) years were followed-up with echo-Doppler examinations for 36 months. The initial spirapril dose was 6 or 12 mg once daily, which was titrated to a minimum of 3 mg and a maximum of 24 mg to keep diastolic blood pressure (DBP) < or = to 95 mmHg. Patient compliance based on tablet counts was 98% (range 95-100%). The mean spirapril dose was 9 +/- 6 mg at 3 months, 9 +/- 6 mg at 12 months, and 15 +/- 9 mg at 36 months. Blood pressure was reduced from 161 +/- 20/107 +/- 6 mmHg at baseline to 137 +/- 11/89 +/- 6 mmHg at 3 months (p < 0.001), 141 +/- 20/89 +/- 4 mmHg at 12 months and 135 +/- 11/87 +/- 6 mmHg at 36 months. The respective values for LVM at baseline and at 3, 12 and 36 months were 340 +/- 71 g, 305 +/- 61 g (p < 0.05 vs baseline), 303 +/- 88 g and 298 +/- 94 g. Cardiac output did not change whereas systemic arteriolar resistance (SAR) was significantly reduced after 3 and 36 months (p < 0.01). Thus, the regression of LVH with spirapril was 10% of LVM at 3 months, 11% at 12 months, and 12% at 36 months. These changes were mainly related to a reduction of LV posterior wall thickness and SAR.
Research Interests:
In the recently published CARE-study, 4,159 patients aged 21-75 years were included and randomised to treatment with pravastatin 40 mg once daily or placebo 3-20 months following a myocardial infarction. Inclusion criteria were a total... more
In the recently published CARE-study, 4,159 patients aged 21-75 years were included and randomised to treatment with pravastatin 40 mg once daily or placebo 3-20 months following a myocardial infarction. Inclusion criteria were a total cholesterol < 6.2 mmol/l and LDL-cholesterol 3.0-4.5 mmol/l. Mean follow-up time was five years. Average reduction of total cholesterol was 20% and of LDL-cholesterol 28% in the treatment group. The incidence of coronary death or non-fatal myocardial infarction was reduced by 24% (p = 0.003). The cholesterol levels in the CARE-study were similar to those in most western populations and lower than in the 4S study. This must be considered when evaluating the different results of the treatment in the two studies. It seems fair not only to offer statin treatment to patients complying with the 4S inclusion criteria, but also to patients with values as in the CARE population.
Research Interests: Norway, Humans, Female, Male, Follow-up studies, and 6 moreRecurrence, Aged, Middle Aged, Myocardial Infarction, Adult, and Aftercare
Research Interests:
Research Interests:
Research Interests: Eating Disorders, Humans, Male, Hyperthyroidism, Adult, and 3 moreAnorexia, Body Weight, and Hypercalcemia
Research Interests:
Atrioventricular (AV) conduction disturbances in 30 patients with ankylosing spondylitis (Mb. Bechterew) have been examined. Nine patients had AV block I with intermittent AV block II (Wenckebach block), 3 had complete heart block, 1... more
Atrioventricular (AV) conduction disturbances in 30 patients with ankylosing spondylitis (Mb. Bechterew) have been examined. Nine patients had AV block I with intermittent AV block II (Wenckebach block), 3 had complete heart block, 1 patient had atrial fibrillation and another had intermittent sinoatrial (SA) block. Thus, 14 (48%) patients had conduction defects. Electrophysiological investigations in 5 patients with AV block and in 1 patient with SA block revealed that the site of the block was proximal to the bundle of His. Two additional patients had prolonged sinus node recovery time implying dysfunction of the sinus node. An association between aortic valvular insufficiency and conduction disturbances was found, but AV block occurred also in patients without signs of valvular regurgitation. Four patients were treated with a permanent pacemaker and 5 with a temporary pacemaker in connection with aortic valvular surgery.
Research Interests:
Research Interests:
In a placebo-controlled, randomized double-blind study the effect of ICI 141.292 (beta 1-selective beta-blocker with intrinsic sympathomimetic activity = ISA) was studied in 11 patients with severe angina pectoris. The doses used were... more
In a placebo-controlled, randomized double-blind study the effect of ICI 141.292 (beta 1-selective beta-blocker with intrinsic sympathomimetic activity = ISA) was studied in 11 patients with severe angina pectoris. The doses used were 100, 200 and 300 mg once daily. The 24-hour heart rate was significantly reduced by all regimens, and the Holter-monitoring pattern indicated the presence of ISA-effect at least 20 hours after the 300-mg dose. Maximal heart rate and blood pressure were significantly reduced and exercise duration increased during a symptom-limited bicycle exercise test on 200 and 300 mg, but not on 100 mg daily. Resting heart rate and blood pressure were uninfluenced on all regimens. ICI 141.292 is an effective agent in patients with severe angina pectoris. The response pattern suggests the presence of clinically relevant ISA.
Research Interests:
Possible long-term deterioration of social function has been studied in adults over 30 years of age with congenital, isolated ventricular septal defects (VSD). This deterioration may possibly have been caused by brain damage connected... more
Possible long-term deterioration of social function has been studied in adults over 30 years of age with congenital, isolated ventricular septal defects (VSD). This deterioration may possibly have been caused by brain damage connected with open heart surgery performed after age 10 years. Thirty-five patients with a mean age of 39 (range 31-61) years have been followed up for an average of 15 (3-21) years when restudied after surgical repair of VSD performed at a mean age of 23 (10-51) years (Group 1). Their social status was compared with 61 non-operated subjects with basically smaller defects, mean age 43 (31-73) years, who had been followed up for an average of 14 (3-21) years. Group 1 had a higher educational level, were less stressed at work, had a higher gross income (NS) and were less physically disabled (p less than 0.01). Both groups had a higher educational level than normal 40-year-old Norwegians. The percentages receiving disablement pension were 12% in group 1 and 13% in...
Research Interests:
Prodromal symptoms within four weeks prior to an acute event leading to coronary care unit admission have been studied in 276 consecutive patients interviewed within 24 hours after arrival at hospital. Coronary heart disease (CHD) was... more
Prodromal symptoms within four weeks prior to an acute event leading to coronary care unit admission have been studied in 276 consecutive patients interviewed within 24 hours after arrival at hospital. Coronary heart disease (CHD) was diagnosed in 237 patients, 140 of whom did develop acute myocardial infarction (AMI) (Group 1) and 97 who did not (Group 2). Of the remainder, 15 had miscellaneous heart diseases (Group 3) and 24 no heart disease (Group 4). Unstable angina pectoris was equally frequent among CHD patients with and without development of AMI and was related to a higher hospital mortality in AMI patients. Less specific symptoms occurred with equal frequency in the four groups. Patients who developed AMI were not possible to identify by prodromal symptoms.
Research Interests:
Echocardiographic measurement of left ventricular (LV) end-diastolic dimensions and mass (M) were made at baseline, at 3 and 12 months of a randomized trial comparing atenolol 50/100 mg od. and hydrochlorothiazide 25/50 mg+amiloride 5 mg... more
Echocardiographic measurement of left ventricular (LV) end-diastolic dimensions and mass (M) were made at baseline, at 3 and 12 months of a randomized trial comparing atenolol 50/100 mg od. and hydrochlorothiazide 25/50 mg+amiloride 5 mg od. (co-amiloride) in 100 men with mild to moderate hypertension. Data from 48 subjects controlled adequately on drug monotherapy and completing 12 months treatment are reported (31 randomized to atenolol and 17 to co-amiloride). Left ventricular mass was measured with the Penn convention at the R and P wave respectively. A significant reduction of LVM was noted after one year in both groups (p < 0.05) when measured at the R, but not at the P wave. Measurements according to American Society of Echocardiography (ASE method) at the Q wave revealed a significant reduction of LV wall thickness (p < 0.01) and an increase of LV internal diameter (p < 0.01) with atenolol. In the co-amiloride group non-significant reductions of LV dimensions were observed. Principally similar changes were observed with measurements at the P wave (National Institute of Heart method) in both groups, but LV wall thickness was greater and LV internal diameter smaller than at the Q wave. With similar effect on LVM, the mechanisms in reducing LVM were different between the two drugs. Left ventricular dimensions differed when assessed with the two methods applied, stressing the need for careful standardization in relation to the cardiac cycle in serial echocardiographic measurements.
Research Interests:
Since the publication of the large trials on streptokinase and aspirin improving mortality related to an acute ST-elevation myocardial infarction (STEMI) there has been numerous studies on improving treatment results with new... more
Since the publication of the large trials on streptokinase and aspirin improving mortality related to an acute ST-elevation myocardial infarction (STEMI) there has been numerous studies on improving treatment results with new fibrinolytics, adjuvant heparin therapy and primary percutaneous intervention (PCI). The aim of the present overview is, in a historic perspective, to link some of the pathophysiology of mechanisms related to plaque rupture and following thrombosis to the effects of drug combinations and PCI observed in major clinical trials conducted in patients with STEMI. The overview comprises short analyses of the initial streptokinase trials (GISSI-1 and ISIS-2), the comparisons between streptokinase and tissue plasminogen activator (rt-PA) and the role of adjuvant heparin treatment (GISSI-2, ISIS-3, GUSTO I). Also included is the comparison between the new bolus-teplases and traditional, accelerated infusion of rt-PA (GUSTO III and ASSENT-2) and between unfractionated heparin (UFH) and low molecular weight heparin (LWMH) given in addition to tenecteplase (ASSENT-3). The pathophysiology of the antiplatelet and antithrombin effects is described, in order to elucidate the treatment differences observed in the trials. In addition, the role of primary PCI is discussed in view of the results in a recent meta-analysis of controlled comparisons with fibrinolytic therapy. Based upon these trials it seems that the optimal thrombolytic treatment is a combination of a bolus-teplase (tenecteplae) and LMWH given on top of aspirin. Primary PCI may be the most optimal treatment, provided given early following STEMI (<1 h), but whether PCI is the best alternative for all patients with STEMI is still a matter of debate. During the last 15 years the optimal antithrombotic treatment of STEMI has developed from a combination of streptokinase and aspirin to the new bolus-teplases combined with LMWH and aspirin. The use of primary PCI may be a better alternative than fibrinolytic therapy, but such a statement needs confirmation in a large comparison between PCI and a quick infusion of modern fibrinolytic agents.
Research Interests:
Research Interests:
... disease. Eur Heart J. 2004; 25:1454Á/70. 3. Rationale and design of GRACE (Global Registry of Acute Coronary Events). Project: A ... failure. Lancet. 1993;342:821Á/8. 8. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical ...
Research Interests:
Research Interests:
Research Interests: Sex, Logistic Regression, Electrocardiography, Humans, Age, and 16 moreHypertension, Hemodynamics, Left Ventricular Assist Device, Female, Male, Atrial Fibrillation, Clinical Sciences, Aged, Middle Aged, Body Mass, Size, Left ventricular hypertrophy, Ejection Fraction, Logistic Models, Mitral regurgitation, and Left Atrium
Research Interests:
Research Interests: Treatment, Risk assessment, Cardiovascular Risk, Stroke, Humans, and 24 moreHypertension, Cox Regression, Female, Male, Atrial Fibrillation, Follow-up studies, Incidence, Risk factors, Multiple Linear Regression, Clinical Sciences, Aged, Middle Aged, Risk Factor, Left ventricular hypertrophy, Clinical Assessment, Cardiovascular Diseases, Risk Factors, Risk Assessment, Losartan, Predictive value of tests, Time varying, Mitral regurgitation, Atenolol, and Left Atrium
Lifestyle measures of coronary heart disease (CHD) prevention have been overshadowed by the efficacy of drug treatments. This is particularly the case in the setting of secondary prevention where the benefits of lipid lowering,... more
Lifestyle measures of coronary heart disease (CHD) prevention have been overshadowed by the efficacy of drug treatments. This is particularly the case in the setting of secondary prevention where the benefits of lipid lowering, anti-platelet and anti-hypertensive drugs have been emphasised in numerous trials. Lifestyle measures address several CHD risk factors at once and are generally free of serious side effects. The objective of the present study was to determine whether a comprehensive programme of lifestyle modification could favourably influence dietary and exercise habits in addition to smoking cessation over two years. In addition, an attempt was made to evaluate if this programme could favourably influence the five-year CHD-risk in the male population included in the study. A total of 197 patients with proven coronary heart disease were included and randomised to a lifestyle intervention programme or to usual care. Follow-up was after a period of two years. Intervention comprised a low fat diet, regular exercise, smoking cessation, psychosocial support and education, delivered by nurses on the rationale for pharmacological and lifestyle measures. Usual care comprised follow-up in the routine outpatient clinic. Both groups were given the same comprehensive medication according to recent guidelines. Patients in the lifestyle intervention group reduced the intake of saturated fat, sugar and cholesterol (P<0.001), increased their exercise level (P<0.01) and stopped smoking (P<0.05) when compared with the usual care group. A sub-analysis of the influence of five-year CHD calculated risk in males resulted in a relative risk reduction of 22% (95% confidence intervals 9-35). Although significant, this result must be interpreted with caution due to poor statistical power and reproducibility of the method. In the presence of modern drug treatments for secondary cardiovascular disease prevention it remains possible through a favourable diet, exercise and smoking cessation to show an additional reduction in the five-year risk for CHD in males.
Research Interests:
Research Interests:
Left ventricular hypertrophy (LVH), diagnosed by ECG and echocardiography, is commonly associated with coronary heart disease. Hypertensive patients with LVH and myocardial ischaemia may be at particular risk. The prevalence of ischaemia... more
Left ventricular hypertrophy (LVH), diagnosed by ECG and echocardiography, is commonly associated with coronary heart disease. Hypertensive patients with LVH and myocardial ischaemia may be at particular risk. The prevalence of ischaemia in hypertensive LVH was addressed in THAMES (Tenormin in Hypertension and Myocardial Ischaemia Epidemiological Survey), which comprised 205 men with hypertension. Echocardiography revealed LVH (defined as a left ventricular mass index > or = 130 g m-2) in 140 patients (68%). Of these patients with LVH, myocardial ischaemia was diagnosed on exercise ECG testing in 24%, and by thallium scintigraphy in 14%. Although not proven, a logical approach would be to improve the prognosis by reversing LVH and reducing ischaemia. A recent meta-analysis has indicated that angiotensin-converting enzyme (ACE) inhibitors are the most effective drugs in reversing LVH. But beta-blockers may still be a logical first choice of drug, because of their valuable anti-ischaemic properties.
Research Interests:
ABSTRACT
Research Interests:
Research Interests:
We aim to compare patient characteristics and coronary risk factors among participants and non-participants in a survey of CHD patients. A cross-sectional study explored characteristics and risk factors in patients hospitalized for acute... more
We aim to compare patient characteristics and coronary risk factors among participants and non-participants in a survey of CHD patients. A cross-sectional study explored characteristics and risk factors in patients hospitalized for acute myocardial infarction and/or revascularization. Study data collected from hospital medical records were compared between participants (n = 1127, 83%) and non-participants (n = 229, 16%), who did not consent to participation in the clinical study. Non-participants showed statistically higher prevalence of women (28% versus 21%), ethnic minorities (6% versus 3%), patients living alone (26% versus 19%), depression (19% versus 6%), anxiety (9% versus 3%), hypertension (54% versus 43%) and diabetes (24% versus 17%). Significantly higher multi-adjusted odds ratios were found for Charlson comorbidity index 3.4 (95% confidence interval (CI), 2.8, 4.3) and depression 14.5 (4.4, 121.5) in non-participants. Non-participants do have higher prevalence of important coronary risk factors compared to participants, and risk factor control may thus be overestimated in available prevention studies. Patients with somatic comorbidity and depression appear to be at particular risk of non-participation in the present study. New strategies accounting for the causes of nonadherence are important to improve secondary prevention in CHD.
Evidence suggests that inflammatory mediators contribute to development and progression of chronic heart failure. We therefore tested the hypothesis that immunomodulation might counteract this pathophysiological mechanism in patients. We... more
Evidence suggests that inflammatory mediators contribute to development and progression of chronic heart failure. We therefore tested the hypothesis that immunomodulation might counteract this pathophysiological mechanism in patients. We did a double-blind, placebo-controlled study of a device-based non-specific immunomodulation therapy (IMT) in patients with New York Heart Association (NYHA) functional class II-IV chronic heart failure, left ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months. Patients were randomly assigned to receive IMT (n=1213) or placebo (n=1213) by intragluteal injection on days 1, 2, 14, and every 28 days thereafter. Primary endpoint was the composite of time to death from any cause or first hospitalisation for cardiovascular reasons. The study continued until 828 primary endpoint events had accrued and all study patients had been treated for at least 22 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00111969. During a mean follow-up of 10.2 months, there were 399 primary events in the IMT group and 429 in the placebo group (hazard ratio 0.92; 95% CI 0.80-1.05; p=0.22). In two prespecified subgroups of patients--those with no history of previous myocardial infarction (n=919) and those with NYHA II heart failure (n=689)--IMT was associated with a 26% (0.74; 0.57-0.95; p=0.02) and a 39% (0.61; 95% CI 0.46-0.80; p=0.0003) reduction in the risk of primary endpoint events, respectively. Non-specific immunomodulation may have a role as a potential treatment for a large segment of the heart failure population, which includes patients without a history of myocardial infarction (irrespective of their functional NYHA class) and patients within NYHA class II.
Research Interests:
Little is known about regional differences in the incidence of acute and elective invasive coronary procedures in Norway. Such information is important in the planning of new invasive centres. In this prospective study all patients... more
Little is known about regional differences in the incidence of acute and elective invasive coronary procedures in Norway. Such information is important in the planning of new invasive centres. In this prospective study all patients referred to coronary angiography at the Rikshospitalet University Hospital in Oslo (100 km remote) from the county of Vestfold (218,000 inhabitants) from 1 December 2002 to 30 November 2003 were included. Referrals were categorised as acute or elective. Based upon the discharge summaries from Oslo, all coronary angiographies, percutaneous interventions and coronary artery bypass grafts were registered. A total of 760 patients were referred, of whom 746 (98 %) underwent coronary angiography (19 % acutely). They were treated as follows: percutaneous coronary intervention, n = 295 (31 % acutely); coronary artery bypass grafting, n = 123 and conservative treatment, n = 342. Based upon these results, the incidence figures for 100,000 inhabitants per year in 2003 were similar to the nation-wide average for percutaneous interventions per year in Norway in 2001 and approximately 30 % below that average for 2003. Therefore, in the planning of an optimal peripheral catheterisation laboratory, the population basis has to be calculated from the local incidence of procedures, since there are obviously significant regional differences in the use of such procedures.
Research Interests:
In a population-based study including 35,218 infants born alive during the 15-y period 1982-96, 360 (1%) were diagnosed as having a congenital heart defect (CHD). At a follow-up 3-18 y after birth (median 9.5 y) 154 patients (42.8%) were... more
In a population-based study including 35,218 infants born alive during the 15-y period 1982-96, 360 (1%) were diagnosed as having a congenital heart defect (CHD). At a follow-up 3-18 y after birth (median 9.5 y) 154 patients (42.8%) were spontaneously cured; of these, 142 (92.2%) had ventricular septal defects (VSDs). Forty-two patients (11.7%) died, 22 of these (52.4%) during the neonatal period (0-28 d after birth). A total of 119 patients (33.1%) underwent therapeutic procedures (surgery, catheter interventions), 24 (20.2%) of whom died. Of the 95 children surviving therapeutic procedures, 54 (56.8%) had their defects completely repaired, while 41 (43.2%) had residual defects or cardiac sequelae, often of minor importance. In 69 children (19.2%) with persistent non-operated defects, 43 (62.3%) had VSDs. A chromosomal disorder, syndrome or associated extracardiac malformation occurred in 72 children (20%). The study underlines the broad variety in severity of CHDs, with a high neonatal mortality rate as well as a high rate of spontaneous cure. It is estimated that 25% of infants born with a CHD will grow into adult age with persistent non-operated defects, residual defects or cardiac sequelae after therapeutic procedures.
Research Interests:
Pre-hospital thrombolysis is a relatively new treatment modality in Norway. The present study is a county-based evaluation of the first phase of this procedure after its introduction in 2002. This is a retrospective cohort study of all... more
Pre-hospital thrombolysis is a relatively new treatment modality in Norway. The present study is a county-based evaluation of the first phase of this procedure after its introduction in 2002. This is a retrospective cohort study of all patients who, over a nine-month period, had a pre-hospital ECG taken by paramedics and transmitted to the county's two coronary care units. The medical records of all patients who received pre-hospital thrombolysis were analysed and compared with those who received in-hospital thrombolysis over the same period. A pre-hospital ECG was successfully taken and transmitted in 840 patients. Pre-hospital thrombolytic therapy was given to 45 (5.4%) patients, of whom 38 (84%) developed ST-elevation myocardial infarction (STEMI). Over the same period, 32 patients received in-hospital thrombolysis, of whom 28 (87%) developed STEMI. Among the 738 hospitalised patients who did not receive pre-hospital thrombolytic therapy, 218 (28%) had a diagnosis of acute coronary syndrome, 258 (35%) had established coronary heart disease but no evidence of coronary ischaemia, while 262 (36%) had no evidence of coronary heart disease at all. Median call-to-thrombolysis time was 42 minutes (range 21-75). The findings indicate good paramedical pre-hospital routines with short call-to-thrombolysis-time, but the routines for pre-hospital ECG and thrombolytic therapy need reassessment.
Research Interests:
A 62-year-old male developed a large posterior left ventricular aneurysm diagnosed 6 months after a sustained myocardial infarction. Coronary angiography revealed a proximal occlusion of the circumflex artery, two 75% stenoses of the... more
A 62-year-old male developed a large posterior left ventricular aneurysm diagnosed 6 months after a sustained myocardial infarction. Coronary angiography revealed a proximal occlusion of the circumflex artery, two 75% stenoses of the right coronary artery and a normal left anterior descending artery. The main clinical indication for surgery was residual bouts of ventricular tachycardia. A successful "mechanical conversion" of this arrhythmia by means of light precordial knocks in the apex region is reported. In this way the patient could be prepared for surgery without using myocardial depressant drugs. The aneurysm was resected, encircling endocardial ventriculotomy was performed and the right coronary artery was grafted. Nine months after the operation the patient is well without the need for antiarrhythmic drugs. The rarity of this condition is stressed and the possible mechanisms of ventricular tachycardia and its treatment in this particular case are discussed.
Research Interests:
Left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular morbidity and mortality. LVH is associated with coronary events, and there is an association between cerebrovascular disease and increased left ventricular mass... more
Left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular morbidity and mortality. LVH is associated with coronary events, and there is an association between cerebrovascular disease and increased left ventricular mass (LVM). Experimental studies have elucidated the importance of non-myocytic cells inducing increased perivascular and interstitial fibrosis along with thickening of the media of intramyocardial coronary arteries in hypertensive LVH. M-mode echocardiography is the most accepted standard for the diagnosis and quantification of LVH, but some controversies exist regarding the ideal methodology for serial assessment of LVM. It is still a matter of debate whether 2-dimensional echo measurements represent a more accurate method. Hopefully, both the introduction of 3-dimensional echo and new Doppler techniques can provide more accurate measurements of LVM and additional information on changes in myocardial fibrosis and stiffness. Experimental studies have shown that normalization of hypertensive myocardial and coronary artery remodelling take place with drugs like angiotensin converting enzyme (ACE)-inhibitors and calcium antagonists. Two meta-analyses suggest that ACE-inhibitors may be the most efficient drugs in reducing LVM, but a clinical correlate to this assumption is at present not available. There are some indications that regression or progression of LVH assessed by ECG and echocardiography may in fact be related to the incidence of cardiovascular events. But large-scale controlled studies of various treatment regimens are still needed to establish whether drug induced regression can improve the prognosis of hypertensive LVH independent of the antihypertensive effect.
Research Interests:
This project aims to identify socio-demographic, medical and psychosocial factors (study factors) associated with coronary risk control and prognosis, and to test their impact in a representative sample of coronary heart disease (CHD)... more
This project aims to identify socio-demographic, medical and psychosocial factors (study factors) associated with coronary risk control and prognosis, and to test their impact in a representative sample of coronary heart disease (CHD) patients. The first phase includes a cross-sectional study designed to explore the association between the study factors and coronary risk factor control in CHD patients. Data from hospital records, a questionnaire, clinical examination and blood samples were collected. The independent effects of study factors on subsequent coronary events will be explored prospectively by controlling for baseline coronary risk factors. In the second phase, we will test the effect of tailored interventions to modify the study factors associated with unfavourable risk profile in phase I. In all 1366 patients (21% women), aged 18-80 years with a coronary event on average 17 (2-38) months prior to study participation were identified (83% participation rate). Of the 239 patients who refused participation, 229 patients consented to analysis of hospital record data (non- participants). If the study variables contribute to CHD risk factors and prognosis, the present project may be important for the development of prevention programs by tailoring these to the patients perceived needs and behaviour profiles.
We describe two patients suffering from bacterial endocarditis with tricuspid valve envolvement. Both had pulmonary embolism, revealed by scintigraphic lung perfusion examination. The diagnosis was made by transthoracic echocardiography... more
We describe two patients suffering from bacterial endocarditis with tricuspid valve envolvement. Both had pulmonary embolism, revealed by scintigraphic lung perfusion examination. The diagnosis was made by transthoracic echocardiography in one patient and transoesophageal echocardiography in the other. Both received therapy with antibiotics and heparin given intravenously. In one patient the vegetation disappeared. We discuss the epidemiology, diagnosis and treatment of the condition, with special focus on the possible role of heparin.
Research Interests: Echocardiography, Humans, Heparin, Pulmonary Embolism, Male, and 3 moreMiddle Aged, Adult, and Dicloxacillin
ABSTRACT
Ninety-five apparently healthy, non-athletic women aged 24-65 (mean 44) years were screened by Doppler echocardiography for the presence of tricuspid and pulmonary regurgitation (TR and PR). An Irex Meridian system was used. TR was... more
Ninety-five apparently healthy, non-athletic women aged 24-65 (mean 44) years were screened by Doppler echocardiography for the presence of tricuspid and pulmonary regurgitation (TR and PR). An Irex Meridian system was used. TR was diagnosed in the presence of a pansystolic regurgitant jet into the right atrium with a maximal velocity of greater than 1.5 m s-1. Regurgitant flow throughout diastole was diagnostic for PR. Right-sided regurgitation was found in 43 women (Group 1), 22 with TR, 12 with PR, and nine with combined TR and PR. The remaining 52 women were studied as a control group (Group 2). Group 1 had a significantly larger heart size on X-ray (P less than 0.025) and left ventricular end systolic diameter assessed from M-mode echocardiography (P less than 0.05) than did Group 2. The possible clinical significance of the valvular regurgitation was assessed by using a standardized symptom-limited exercise test on an ergometer bicycle. In Group 1, the mean cumulative work achieved was 7008 (+/- 1630) kpm, and in Group 2 6363 (+/- 1633) kpm (P less than 0.05). TR and PR occurring in otherwise healthy women does not seem to impair physical exercise performance.
Research Interests:
Several epidemiological studies world-wide have shown that serum (s)-cholesterol is a major risk factor for development of atherosclerosis. The risk of coronary heart disease increases with increasing s-cholesterol, and the relationship... more
Several epidemiological studies world-wide have shown that serum (s)-cholesterol is a major risk factor for development of atherosclerosis. The risk of coronary heart disease increases with increasing s-cholesterol, and the relationship is continuous and curvilinear, with an increase with s-cholesterol levels greater than or equal to 5.2 mmol/l (200 mg/dl). Therefore, the recommended s-cholesterol is below 5.2 mmol/l. The purpose of this study was to investigate the level of s-cholesterol in a group of apparently healthy Norwegians aged 20-70 years in 1987. 94 men and 93 women were examined. We found, as others have shown before, that s-cholesterol increases significantly with age both among men and among women. The intersexual differences are not statistically significant. 69% of the total group had s-cholesterol greater than or equal to 5.2 mmol/l. These findings should have consequences for dietary policy in Norway.
Research Interests:
We examined 87 men with moderate hypertension (diastolic blood pressure, DPB, greater than or equal to 95 and less than 110 mmHg) (mean age 45, range 22-64, years) with echocardiography and maximal ergometer bicycle test. Left ventricular... more
We examined 87 men with moderate hypertension (diastolic blood pressure, DPB, greater than or equal to 95 and less than 110 mmHg) (mean age 45, range 22-64, years) with echocardiography and maximal ergometer bicycle test. Left ventricular mass index (LVMI) was calculated according to the Penn convention. Mean LVMI was 126 (60-210) g/m2. The maximal systolic blood pressure (SBP) during exercise was on average 217 (155-260) mmHg. Linear regression analysis revealed a significant correlation between LVMI and SBP at rest (r = 0.48, P less than 0.001) and during exercise (r = 0.39, P less than 0.001). Multiple regression analysis correcting for differences in age, cumulative work and cholesterol level revealed a significant correlation between LVMI and SBP at rest (t = 4.07, P less than 0.0001) and during exercise (t = 3.25, P = 0.002). Thus in patients with established, moderate hypertension exercise SBP is not more predictable for LVMI than is SBP at rest.
Research Interests:
The value of exercise-redistribution thallium-201 perfusion scintigraphy (SPECT; single photon emission computed tomography) in the diagnosis of coronary artery disease was evaluated in 23 patients (one patient tested twice) who were... more
The value of exercise-redistribution thallium-201 perfusion scintigraphy (SPECT; single photon emission computed tomography) in the diagnosis of coronary artery disease was evaluated in 23 patients (one patient tested twice) who were subsequently submitted to coronary angiography. Reversible perfusion defects indicating myocardial ischemia were found in 22 patients, of whom 18 had angiographically significant coronary artery stenoses. Two patients had negative thallium scans, one had a normal angiogram and one had single vessel disease. Thus 18 of 19 patients with angiographically verified coronary heart disease had a positive thallium scan. The majority of patients with left main stenosis and triple vessel disease had scintigraphic evidence of double or triple vessel disease. The scintigraphic method identified the correct anatomical localization in 73% of the angiographically verified coronary artery stenoses. In conclusion, a positive exercise-redistribution thallium scan had a high predictive value in the diagnosis of coronary artery disease, whereas its value in estimating the number and localization of stenoses was more limited.
Research Interests:
In a population based study including 35,218 infants born alive during the 15-year period 1982-1996, 360 (1%) were diagnosed having a congenital heart defect (CHD). At a follow-up 3-18 years later (median 9.5 years) 154 patients (42.8%)... more
In a population based study including 35,218 infants born alive during the 15-year period 1982-1996, 360 (1%) were diagnosed having a congenital heart defect (CHD). At a follow-up 3-18 years later (median 9.5 years) 154 patients (42.8%) were spontaneously cured, of whom 142 (92.2%) had ventricular septal defects (VSD). 42 patients (11.7%) had died, 22 of whom (52.4%) during the neonatal period (0-28 days after birth). A total of 119 patients (33.1%) underwent therapeutic procedures (surgery, catheter interventions), of whom 24 (20.2%) died. Of the 95 children surviving therapeutic procedures 54 (56.8%) had their defects completely repaired, while 41 (43.2%) had residual defects or cardiac sequelae, often of minor importance. Of 69 children (19.2%) with persistent untreated defects, 43 (62.3%) had VSD. A chromosomal disorder, various syndromes or extracardiac malformations occurred in 72 children (20%). The study underlines the fact that CHD presents itself in varying degrees of severity, including a high neonatal mortality rate as well as a high rate of spontaneous cure.